FDA advisers say AstraZeneca diabetes drug label should bear warning of heart failure risk

April 15, 2015 10:10 AM

18 0

WASHINGTON — Federal health advisers say AstraZeneca's Onglyza and a related diabetes drug should carry new information about a possible association with heart failure and death.

The Food and Drug Administration's panel of diabetes experts voiced concern about data suggesting Onglyza and Kombiglyze can increase hospitalization due to heart failure and overall mortality. The panel voted 14-1 that that information should appear on the drugs' prescribing labeling. Yet the panel...

Read more

To category page